DK114978B - Fremgangsmåde til fremstilling af (3-amino-pyrazinoyl)-guanidin-forbindelser eller salte heraf. - Google Patents

Fremgangsmåde til fremstilling af (3-amino-pyrazinoyl)-guanidin-forbindelser eller salte heraf.

Info

Publication number
DK114978B
DK114978B DK512263AA DK512263A DK114978B DK 114978 B DK114978 B DK 114978B DK 512263A A DK512263A A DK 512263AA DK 512263 A DK512263 A DK 512263A DK 114978 B DK114978 B DK 114978B
Authority
DK
Denmark
Prior art keywords
pyrazinoyl
salts
amino
preparation
guanidine compounds
Prior art date
Application number
DK512263AA
Other languages
Danish (da)
English (en)
Inventor
E Cragoe
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of DK114978B publication Critical patent/DK114978B/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK512263AA 1962-10-30 1963-10-30 Fremgangsmåde til fremstilling af (3-amino-pyrazinoyl)-guanidin-forbindelser eller salte heraf. DK114978B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23423062A 1962-10-30 1962-10-30
US313315A US3313813A (en) 1962-10-30 1963-10-07 (3-amino-5, 6-disubstituted-pyrazinoyl) guanidines

Publications (1)

Publication Number Publication Date
DK114978B true DK114978B (da) 1969-08-25

Family

ID=26927694

Family Applications (4)

Application Number Title Priority Date Filing Date
DK512263AA DK114978B (da) 1962-10-30 1963-10-30 Fremgangsmåde til fremstilling af (3-amino-pyrazinoyl)-guanidin-forbindelser eller salte heraf.
DK453364AA DK116943B (da) 1962-10-30 1964-09-14 Fremgangsmåde til fremstilling af (3-amino-5,6-disubstituerede-pyrazinoyl)-guanidinforbindelser eller syreadditionssalte deraf.
DK619765AA DK115403B (da) 1962-10-30 1965-12-02 Fremgangsmåde til fremstilling af (3-amino-pyrazinoyl)-guanidiner.
DK619865AA DK114557B (da) 1962-10-30 1965-12-02 Fremgangsmåde til fremstilling af pteridin-forbindelser.

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK453364AA DK116943B (da) 1962-10-30 1964-09-14 Fremgangsmåde til fremstilling af (3-amino-5,6-disubstituerede-pyrazinoyl)-guanidinforbindelser eller syreadditionssalte deraf.
DK619765AA DK115403B (da) 1962-10-30 1965-12-02 Fremgangsmåde til fremstilling af (3-amino-pyrazinoyl)-guanidiner.
DK619865AA DK114557B (da) 1962-10-30 1965-12-02 Fremgangsmåde til fremstilling af pteridin-forbindelser.

Country Status (13)

Country Link
US (1) US3313813A (sl)
BE (1) BE639386A (sl)
BR (1) BR6354164D0 (sl)
CH (1) CH465617A (sl)
CY (1) CY440A (sl)
DE (2) DE1795438C2 (sl)
DK (4) DK114978B (sl)
FI (1) FI47102C (sl)
FR (1) FR1563612A (sl)
GB (1) GB1066855A (sl)
MY (1) MY6900026A (sl)
NL (2) NL142413B (sl)
SE (1) SE321230B (sl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6409714A (sl) * 1962-10-30 1965-10-01
US3472848A (en) * 1966-11-17 1969-10-14 Merck & Co Inc 3-hydroxy and 3-mercapto-pyrazinoyl-guanidines,corresponding ethers and thioethers and processes for their preparation
US3948895A (en) * 1971-09-28 1976-04-06 E. I. Du Pont De Nemours And Company Synthesis of 3,5-diaminopyrazinoic acid from 3,5-diamino-2,6-dicyanopyrazine and intermediates
US4085211A (en) * 1975-12-15 1978-04-18 Merck & Co., Inc. Pyrazinecarboxamides and processes for preparing same
US4087526A (en) * 1976-07-23 1978-05-02 Merck & Co., Inc. (3-Amino-5-substituted-6-fluoropyrazinoyl or pyrazamido)-guanidines and their derivatives bearing substituents on the guanidino nitrogens
US4208413A (en) * 1977-03-04 1980-06-17 Merck & Co., Inc. N-Pyrazinecarbonyl-N'-alkoxycarbonyl and N',N"-bis(alkoxycarbonyl)guanidines and processes for preparing same
US4108859A (en) * 1977-06-06 1978-08-22 The Dow Chemical Company Microbicidal (pyridinylamino) alkyl guanidines
US4140776A (en) * 1977-09-16 1979-02-20 Merck & Co., Inc. N-pyrazinecarbonyl-N'-acylguanidines
US4190655A (en) * 1978-08-28 1980-02-26 Merck & Co., Inc. Amiloride citrate
EP0009054A1 (en) * 1978-09-19 1980-04-02 Merck & Co. Inc. N-Pyrazinecarbonyl-N'-substituted-sulfamoyl-guanidine and processes for preparing same
US4246406A (en) * 1979-03-27 1981-01-20 Merck & Co., Inc. Heterocyclic substituted pyrazinoylguanidines
US4224447A (en) * 1979-03-27 1980-09-23 Merck & Co., Inc. Novel pyrazinecarboxamides and processes for preparing same
US4309540A (en) * 1980-05-19 1982-01-05 Merck & Co., Inc. Substituted pyrazinyl-1,2,4-oxadiazoles
US4362724A (en) * 1980-05-19 1982-12-07 Merck & Co., Inc. Method of treating edema and hypertension and pharmaceutical composition therefor in which the active ingredient comprises a novel substituted pyrazinyl-1,2,4-oxadiazole and a kaliuretic diuretic
US4454132A (en) * 1981-03-16 1984-06-12 Merck & Co., Inc. Pharmaceutical compositions of novel substituted pyrazinyl-1,2,4-oxadiazoles useful in the treatment of edema and hypertension
US4510322A (en) * 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
US4952582A (en) * 1982-01-04 1990-08-28 Beyer Jr Karl H Pyrazinoylguanidine and derivatives thereof having few polar substituents and being useful as hyperuretic agents
US4663322A (en) * 1982-01-04 1987-05-05 Beyer Jr Karl H Antihypertensive hyperuretic and saluretic agent combinations
DE3312516A1 (de) * 1983-04-07 1984-10-11 Brigitte Dr. 7400 Tübingen Pfeiffer Kernsubstituierte phenylalkylenguanidinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
US4604394A (en) * 1984-10-01 1986-08-05 Merck & Co., Inc. Antiarrhythmic compositions and method
DE3925847A1 (de) * 1989-08-04 1991-02-07 Huels Chemische Werke Ag Verfahren zur herstellung von 3-aminopyrazin-2-carbonsaeuremethylester
KR930701992A (ko) * 1990-10-05 1993-09-08 웨인 알.조운즈 환자의 폐에 잔존하는 점액 분비물의 제거 방법
US5304125A (en) * 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
TW213903B (sl) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
DE4337609A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
TW372967B (en) * 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5801177A (en) * 1995-12-14 1998-09-01 Beyer, Jr.; Karl H. Method for controlling and/or lowering serum glucose and fatty acid concentrations and hypertensive blood pressure in non-insulin-dependent diabetic patients
US5877217A (en) * 1995-12-26 1999-03-02 Alteon Inc. N-acylaminoalkyl-hydrazinecarboximidamides
ID29198A (id) * 1997-08-29 2001-08-09 Univ North Carolina Pemakaian uridin 5'-difosfat dan persamaannya untuk mengobati penyakit paru-paru
WO2000023023A1 (en) * 1998-10-20 2000-04-27 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
WO2000044382A1 (en) * 1999-01-29 2000-08-03 BEYER, Camille, F. Composition and method for treating diabetes
US6475509B1 (en) 1999-07-19 2002-11-05 The University Of North Carolina At Chapel Hill Covalent conjugates of sodium channel blockers and active compounds
CZ20031367A3 (cs) 2000-11-21 2003-10-15 Sankyo Company, Limited Farmaceutický prostředek obsahující antagonistu receptoru pro angiotensin II a jedno nebo více diuretik a jeho použití
US6858614B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
EP1501514B1 (en) * 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
ATE502635T1 (de) 2002-08-19 2011-04-15 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
AU2004248859C1 (en) * 2003-06-26 2011-11-24 Biotron Limited Antiviral acylguanidine compounds and methods
CA2529949C (en) 2003-06-26 2013-08-06 Biotron Limited Antiviral compounds and methods
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
US7064129B2 (en) 2003-08-18 2006-06-20 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
EP1670475A4 (en) * 2003-08-18 2009-04-15 Parion Sciences Inc ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US20070099968A1 (en) * 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
CA2630920A1 (en) * 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのcetp阻害剤としてのn−((3−ベンジル)−2,2−(ビス−フェニル)−プロパン−1−アミン誘導体
EP2211956A4 (en) 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
TWI432198B (zh) * 2008-02-26 2014-04-01 Parion Sciences Inc 多芳香族鈉通道阻斷劑
DE102008053024B4 (de) 2008-10-24 2015-04-30 RUHR-UNIVERSITäT BOCHUM Verwendung von Amilorid-Derivaten zur Bekämpfung von Insekten und Milben
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US9072738B2 (en) 2011-06-27 2015-07-07 Parion Sciences, Inc. Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
PL2855435T3 (pl) 2012-05-29 2018-10-31 Parion Sciences, Inc. Amidy o strukturze podobnej do dendrymerów, wykazujące aktywność blokerów kanałów sodowych, do leczenia zespołu suchego oka i innych chorób śluzówki
US9593084B2 (en) 2012-12-17 2017-03-14 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
WO2014099673A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのn−ピペリジン−3−イルベンズアミド誘導体
JP6449870B2 (ja) * 2013-07-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN109476599A (zh) * 2016-07-29 2019-03-15 东丽株式会社 胍衍生物和其医药用途
JP7128969B2 (ja) 2019-01-18 2022-08-31 アストラゼネカ・アクチエボラーグ Pcsk9阻害剤及びその使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL299929A (sl) * 1962-10-30

Also Published As

Publication number Publication date
FI47102B (sl) 1973-05-31
DK114557B (da) 1969-07-14
DK116943B (da) 1970-03-02
MY6900026A (en) 1969-12-31
FI47102C (fi) 1973-09-10
CY440A (en) 1968-05-18
SE321230B (sl) 1970-03-02
NL299931A (sl)
DK115403B (da) 1969-10-06
DE1470053A1 (de) 1969-06-26
DE1795438C2 (de) 1974-04-11
FR1563612A (sl) 1969-04-18
DE1795438B1 (de) 1973-09-06
US3313813A (en) 1967-04-11
BR6354164D0 (pt) 1973-09-18
NL142413B (nl) 1974-06-17
GB1066855A (en) 1967-04-26
CH465617A (de) 1968-11-30
BE639386A (sl)

Similar Documents

Publication Publication Date Title
DK114978B (da) Fremgangsmåde til fremstilling af (3-amino-pyrazinoyl)-guanidin-forbindelser eller salte heraf.
DK121866B (da) Fremgangsmåde til fremstilling af aryloxyalkanolaminderivater eller salte deraf.
DK108310C (da) Fremgangsmåde til fremstilling af (3-aminopyrazinamido)-guanidinforbindelser eller syreadditionssalte heraf.
DK131907B (da) Fremgangsmåde til fremstilling af en alfa-aminobenzylpenicillin eller salte deraf.
DK104237C (da) Fremgangsmåde til fremstilling af imidazolforbindelser eller salte deraf.
DK107876C (da) Fremgangsmåde til fremstilling af phenylethanolaminer eller salte heraf.
DK111567B (da) Fremgangsmåde til fremstilling af piperidinderivater eller salte deraf.
DK118823B (da) Fremgangsmåde til fremstilling af 2-mercaptothiazolyl-benzimidazol-forbindelser eller salte deraf.
DK113576B (da) Fremgangsmåde til fremstilling af benzensulfonyl-semicarbazider eller salte deraf.
DK102805C (da) Fremgangsmåde til fremstilling af indoloquinolizinderivater eller salte heraf.
DK104064C (da) Fremgangsmåde til fremstilling af derivater af 4-sulfanilamid-pyrimidin eller salte deraf.
DK100117C (da) Fremgangsmåde til fremstilling af 3-cyclopropylaminomethylindolforbindelser eller salte heraf.
DK108863C (da) Fremgangsmåde til fremstilling af 1-halogenphenylethyl-2-methyl-1,2,3,4-tetrahydro-iso-quinolinforbindelser eller salte deraf.
DK109206C (da) Fremgangsmåde til fremstilling af desoxo-schizozygin eller desoxo-dihydro-schizozygin eller salte deraf.
DK100620C (da) Fremgangsmåde til fremstilling af 2-α-hydroxyalkyl-4-quinazoloner eller salte deraf.
DK104060C (da) Fremgangsmåde til fremstilling af α-aminobenzylpenicillin eller salte deraf.
DK105465C (da) Fremgangsmåde til fremstilling af 20-alkyl-20-aminosteroider eller salte deraf.
DK118244B (da) Fremgangsmåde til fremstilling af α-hydroxypenicilliner eller salte deraf.
DK118243B (da) Fremgangsmåde til fremstilling af α-hydroxypenicilliner eller salte deraf.
DK101361C (da) Fremgangsmåde til fremstilling af polyhydroxybenzylhydrazinforbindelser eller salte deraf.
DK115037B (da) Fremgangsmåde til fremstilling af hydroxybenzensulfonylurinstoffer eller disses salte.
DK98301C (da) Fremgangsmåde til fremstilling af 4-sulfonamido-5,6-dialkoxy-pyrimidiner eller salte deraf.
DK102182C (da) Fremgangsmåde til fremstilling af 3-sulfanilamido-4,5-dialkyl-isoxazoler eller salte deraf.
DK102518C (da) Fremgangsmåde til fremstilling af benzodiazepinforbindelser eller salte deraf.
DK95588C (da) Fremgangsmåde til fremstilling af 1,2,3,4,5,6,7,8-octahydro-iso-quinolinforbindelser eller salte deraf.